How Much Does Vyvanse Cost in Indiana in 2026?

Vyvanse Retail Pricing Across Indiana Pharmacies

The gap between the sticker price and what Indiana patients actually pay is enormous. Takeda's wholesale acquisition cost (WAC) for Vyvanse sits at $390 per month, a figure that reflects the branded manufacturer price rather than what most people hand over at the counter [1]. Across Indiana retail pharmacies in 2026, cash-pay pricing with available discount tools averages around $35 per month.

Several factors drive that difference. Pharmacy benefit managers negotiate rebates on branded stimulants, and GoodRx-style discount aggregators have pushed transparent pricing into CVS, Walgreens, and independent pharmacies statewide. Indiana's pharmacy density also plays a role. The state has more than 1,400 licensed retail pharmacies serving a population of roughly 6.8 million, which creates competition that keeps cash pricing closer to acquisition cost than in less saturated markets.

Prices still vary by location. An Indianapolis CVS might quote $340 without a discount card while a Kroger pharmacy in Fort Wayne lists $298 for the same 30-capsule fill. Always compare quotes from at least three pharmacies before filling. Indiana law permits pharmacists to provide price information over the phone, so a five-minute call can save hundreds of dollars [2].

Indiana Medicaid and Vyvanse Coverage

Indiana Medicaid does not cover Vyvanse for ADHD or binge eating disorder as of 2026. The Indiana Health Coverage Programs (IHCP) preferred drug list restricts lisdexamfetamine coverage to limited formulary exceptions, and the drug is not included in the standard behavioral health medication tier for attention deficit conditions [3].

This means Hoosier Healthwise, Healthy Indiana Plan (HIP), and traditional Medicaid beneficiaries cannot fill Vyvanse without a prior authorization override, which is rarely granted when cheaper generic alternatives like mixed amphetamine salts (generic Adderall) remain on formulary. The Indiana Family and Social Services Administration (FSSA) updates the preferred drug list quarterly, so checking the most recent version at in.gov/medicaid is worth doing before each refill cycle.

For patients whose clinicians believe lisdexamfetamine is medically necessary over formulary alternatives, the prior authorization process requires documentation of treatment failure on at least two preferred stimulants. A 2017 study by Wigal et al. demonstrated that lisdexamfetamine's prodrug pharmacokinetics produce a smoother concentration curve compared to immediate-release amphetamine formulations, which may support medical necessity arguments in select cases [4].

Private Insurance Coverage for Vyvanse in Indiana

Most commercial plans available through the Indiana marketplace or employer-sponsored coverage do include Vyvanse, though typically on a Tier 3 (non-preferred brand) formulary position. Copays at Tier 3 commonly range from $40 to $75 per month, depending on the plan design. Some high-deductible health plans (HDHPs) require patients to pay full price until meeting the annual deductible, which can mean $300+ out-of-pocket for early fills in the plan year.

Indiana's three largest commercial insurers, Anthem Blue Cross Blue Shield, CareSource, and MDwise, each handle Vyvanse differently:

• Anthem BCBS Indiana: Covers Vyvanse at Tier 3 with prior authorization required for adults over 65. Typical copay: $50 to $65.
• CareSource Indiana: Covers with step therapy. Patients must trial generic amphetamine salts first. Copay after step therapy: $40 to $60.
• MDwise: Covers Vyvanse for ADHD in patients aged 6 through 17 without prior authorization. Adult coverage requires step therapy documentation.

The Affordable Care Act requires all marketplace plans to cover at least one drug per pharmacologic class, but it does not mandate coverage of a specific branded product. Insurers satisfy this requirement by covering generic mixed amphetamine salts, which means Vyvanse coverage is a plan-by-plan decision rather than a legal guarantee [5].

The Takeda Savings Card: How It Works in Indiana

Takeda offers a manufacturer copay assistance program called the Vyvanse Savings Card that can reduce out-of-pocket costs to as low as $30 per 30-day fill for commercially insured patients. The card is accepted at all major Indiana chain pharmacies and most independents. Eligibility rules are straightforward but carry important exclusions.

Who qualifies:

• Patients with commercial (private) insurance
• Adults and pediatric patients with a valid Vyvanse prescription
• U.S. residents, including Indiana

Who does not qualify:

• Patients covered by any federal or state government program, including Medicaid, Medicare, TRICARE, or VA benefits
• Uninsured patients (Takeda has a separate patient assistance program for this group)
• Cash-pay patients without insurance

The card works by Takeda covering the difference between the patient's copay and the $30 floor, up to a maximum annual benefit that Takeda sets each calendar year. In 2026, the annual cap is $3,600. For a patient with a $65 commercial copay, the card reduces each fill to $30, saving $420 over 12 months [6].

Indiana patients who are uninsured may qualify for the separate Takeda Patient Assistance Program (PAP), which provides Vyvanse at no cost to qualifying individuals below 250% of the federal poverty level. Applications require income documentation and prescriber certification.

Compounded Lisdexamfetamine in Indiana

Compounded lisdexamfetamine is available through licensed 503A compounding pharmacies in Indiana. This is a legal option under both federal law (the Drug Quality and Security Act of 2013) and Indiana Board of Pharmacy regulations, provided the pharmacy operates under a valid patient-specific prescription [7].

503A compounding pharmacies prepare medications in response to individual prescriptions from licensed prescribers. They differ from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions. In Indiana, several 503A pharmacies compound lisdexamfetamine capsules, sometimes at costs below branded Vyvanse.

A few practical notes for Indiana patients considering this route. Compounded lisdexamfetamine is not AB-rated as therapeutically equivalent to branded Vyvanse by the FDA. The active pharmaceutical ingredient is identical, but excipients, capsule formulations, and dissolution profiles may differ. Patients switching from branded Vyvanse to a compounded version should discuss dose verification with their prescriber.

Indiana does not impose additional state-level restrictions on compounding Schedule II controlled substances beyond federal DEA requirements. The prescribing clinician must hold a valid DEA registration, and the prescription must be written for a specific patient with a documented medical need [8].

Telehealth Prescribing of Vyvanse in Indiana

Indiana permits telehealth prescribing of Vyvanse as of 2026. The Indiana Medical Licensing Board allows Schedule II controlled substances to be prescribed via telemedicine when the prescriber conducts an appropriate evaluation, which can include audio-visual consultation [9].

This opens access for patients in rural Indiana counties where psychiatric and ADHD specialty care is limited. According to the Health Resources and Services Administration (HRSA), 57 of Indiana's 92 counties qualify as mental health professional shortage areas [10]. Telehealth-based ADHD evaluation and stimulant prescribing connects patients in these underserved areas with board-certified psychiatrists and psychiatric nurse practitioners without requiring a multi-hour drive to Indianapolis, Fort Wayne, or South Bend.

The DEA's telemedicine prescribing flexibilities, originally introduced during the COVID-19 public health emergency, have been extended through rulemaking that allows initial Schedule II prescriptions via video evaluation under specified conditions. Indiana-licensed prescribers who meet these federal requirements can initiate and maintain Vyvanse prescriptions through telehealth platforms [11].

Indiana patients using telehealth for Vyvanse should confirm that:

1. The prescriber holds an active Indiana medical or advanced practice nursing license
2. The platform uses a DEA-compliant electronic prescribing system (EPCS) for Schedule II transmission
3. The prescription is sent to an Indiana-licensed pharmacy

Comparing Vyvanse to Generic Alternatives Available in Indiana

Vyvanse (lisdexamfetamine) does not yet have an AB-rated generic equivalent on the U.S. market in 2026. Takeda's patent protections and regulatory exclusivities have kept generic lisdexamfetamine off pharmacy shelves, though several manufacturers have filed abbreviated new drug applications (ANDAs) with the FDA [12].

The closest pharmacologic alternatives available as generics in Indiana include:

| Medication | Generic Available | Typical Indiana Cash Price | Duration | |---|---|---|---| | Mixed amphetamine salts IR (generic Adderall) | Yes | $15 to $30/month | 4 to 6 hours | | Mixed amphetamine salts XR (generic Adderall XR) | Yes | $25 to $50/month | 10 to 12 hours | | Dextroamphetamine IR (generic Dexedrine) | Yes | $20 to $40/month | 4 to 6 hours | | Methylphenidate ER (generic Concerta) | Yes | $20 to $45/month | 10 to 12 hours | | Lisdexamfetamine (Vyvanse) | No | $35 to $390/month | 10 to 14 hours |

Lisdexamfetamine's prodrug mechanism distinguishes it from these alternatives. The molecule is pharmacologically inactive until enzymatic cleavage in red blood cells converts it to d-amphetamine, producing a gradual onset and lower peak-to-trough variability. Wigal et al. (2017) measured this pharmacokinetic profile in a crossover study comparing lisdexamfetamine to mixed amphetamine salts XR, finding that lisdexamfetamine produced a more consistent plasma concentration curve over 14 hours (Cmax reached at approximately 3.5 hours post-dose vs. the biphasic peak of MAS-XR) [4].

This pharmacokinetic profile may reduce the abuse potential associated with rapid-onset stimulants, a consideration the FDA weighed when assigning Vyvanse its Schedule II classification with a lower observed rate of "drug liking" in human abuse-potential studies compared to equivalent doses of immediate-release d-amphetamine [1].

Indiana Discount Programs and Manufacturer Assistance

Beyond the Takeda Savings Card, Indiana patients have several additional cost-reduction pathways.

RxAssist and NeedyMeds databases. Both nonprofit directories list active patient assistance programs for lisdexamfetamine. The Takeda PAP (for uninsured patients below 250% FPL) and the Takeda Savings Card (for commercially insured patients) are the two primary programs, but seasonal enrollment windows and eligibility shifts make checking these databases worthwhile at rxassist.org and needymeds.org.

Indiana 340B pharmacies. Federally qualified health centers (FQHCs) and certain hospital outpatient pharmacies participating in the 340B Drug Pricing Program purchase Vyvanse at a steep discount from the WAC price. Indiana has more than 30 FQHCs operating across the state. Patients who receive care at these centers can often fill Vyvanse prescriptions at the on-site or contract pharmacy at 340B pricing, which may be 25% to 50% below standard retail [13].

GoodRx and similar aggregators. These platforms negotiate pharmacy-specific discount rates and typically show Indiana Vyvanse prices between $280 and $340 for cash-pay patients without other discount programs. The $35 average figure cited above reflects the best available pricing when stacking eligible discounts.

Copay accumulators: a caution. Some Indiana commercial plans have adopted copay accumulator programs that prevent manufacturer copay cards from counting toward the annual deductible or out-of-pocket maximum. If your plan uses an accumulator adjustment, the Takeda Savings Card will still reduce your monthly copay, but you may face a large out-of-pocket bill later in the plan year when the card's annual cap is exhausted. Indiana does not currently have a state law prohibiting copay accumulator programs, unlike states such as Arizona and Virginia that have enacted accumulator adjustment restrictions [14].

Dosing, Administration, and Monitoring Basics

Vyvanse is prescribed as a once-daily oral capsule taken in the morning. The FDA-approved dose range for ADHD is 30 mg to 70 mg daily in both pediatric patients (ages 6 and older) and adults. For binge eating disorder in adults, the approved range is 50 mg to 70 mg daily [1].

Clinicians typically initiate treatment at 30 mg and titrate upward in 10 mg or 20 mg increments at weekly intervals based on efficacy and tolerability. Blood pressure and heart rate should be measured at baseline and at each dose adjustment. The American Academy of Pediatrics (AAP) recommends cardiovascular screening before starting stimulant therapy, including a focused cardiac history and physical examination [15].

Common adverse effects reported in clinical trials include decreased appetite (reported in 27% of pediatric patients vs. 4% placebo), insomnia (13% vs. 4%), and dry mouth (5% vs. 1%). Weight loss monitoring is recommended, particularly in pediatric patients, where growth velocity should be tracked at 3-month intervals during the first year of treatment [1].

Indiana prescribers are required to check the Indiana INSPECT database (the state's prescription drug monitoring program) before issuing a new Schedule II prescription and at defined intervals during ongoing treatment. This requirement, codified under Indiana Code 25-1-9.5, applies to both in-person and telehealth prescribers [9].